<DOC>
	<DOCNO>NCT01568294</DOCNO>
	<brief_summary>The purpose study determine tolerate dose pomalidomide also evaluate pharmacokinetics , safety efficacy pomalidomide patient refractory relapsed refractory multiple myeloma .</brief_summary>
	<brief_title>Japanese Phase 1 Study Evaluate Tolerated Dose , Safety , Efficacy Pomalidomide Patients With Refractory Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must ≥ 20 year age time sign informed consent document The subject must understand voluntarily sign informed consent document prior study related assessments/procedures conduct . Must able adhere study visit schedule protocol requirement Subjects must document diagnosis multiple myeloma measurable disease All subject must least 2 prior line antimyeloma therapy . Induction therapy follow stem cell transplant consolidation/maintenance consider one line All subject must either refractory relapsed refractory disease define documented disease progression within 60 day complete last antimyeloma therapy . Primary refractory : Subjects never achieve response well progressive disease ( PD ) previous line antimyeloma therapy . Relapsed refractory : Subjects relapse achieve least stable disease ( SD ) least one prior regimen develop progressive disease ( PD ) within 60 day complete last antimyeloma therapy . Subjects must also undergo prior treatment least 2 cycle lenalidomide least 2 cycle bortezomib ( either separate regimen within regimen ) . All subject must receive adequate prior alkylator therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . Pregnant breastfeeding female Hypersensitivity thalidomide , lenalidomide , dexamethasone ≥ Grade 3 rash prior thalidomide lenalidomide therapy Patients unable unwilling undergo antithrombotic prophylactic treatment eligible participate study Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,000/µL Platelet count &lt; 75,000/µL patient &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/µL patient ≥ 50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min accord CockcroftGault formula Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior RBC transfusion recombinant human erythropoietin use permit ) Serum glutamic oxaloacetic transaminase ( SGOT ) /aspartate aminotransferase ( AST ) serum glutamic pyruvic transaminase ( SGPT ) /alanine aminotransferase ( ALT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) ; ≥ 3.0 x upper limit normal ( ULN ) subject hereditary benign hyperbilirubinaemia Peripheral neuropathy ≥ Grade 2 Patients receive follow within last 14 day initiation study treatment : Plasmapheresis Major surgery ( kyphoplasty consider major surgery ) Radiation therapy Use antimyeloma drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>